BRIEF-Acelrx Receives Ide Approval For Niyad And Advances To A Single Registration Study

Reuters

Oct 03, 2023

Oct 3 (Reuters) - AcelRx Pharmaceuticals Inc :

* ACELRX RECEIVES IDE APPROVAL FOR NIYAD AND ADVANCES TO A SINGLE REGISTRATION STUDY

* ACELRX PHARMACEUTICALS - INVESTIGATIONAL DEVICE EXEMPTION APPROVAL BY FDA ALLOWS ACELRX TO BEGIN PIVOTAL STUDY OF NIYAD

* ACELRX PHARMACEUTICALS - SINGLE REGISTRATION STUDY WITH PRE-AGREED UPON ENDPOINTS PLANNED TO INITIATE IN Q4 2023 WITH TOPLINE DATA EXPECTED MID-2024

* ACELRX PHARMACEUTICALS INC - CLINICAL SITE READINESS IS CURRENTLY UNDERWAY

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2372892255"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2372892255\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2372892255?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-10-03 21:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2372892255","market":"us","top_or_hot":-1,"title":"BRIEF-Acelrx Receives Ide Approval For Niyad And Advances To A Single Registration Study","media":"Reuters","content":"<html><body><p>Oct 3 (Reuters) - <a href=\"https://laohu8.com/S/ACRX\">AcelRx Pharmaceuticals</a> Inc   :</p><p>   * ACELRX RECEIVES IDE APPROVAL FOR NIYAD AND ADVANCES TO A SINGLE REGISTRATION STUDY</p><p>   * ACELRX PHARMACEUTICALS - INVESTIGATIONAL DEVICE EXEMPTION APPROVAL BY FDA ALLOWS ACELRX TO BEGIN PIVOTAL STUDY OF NIYAD</p><p>   * ACELRX PHARMACEUTICALS - SINGLE REGISTRATION STUDY WITH PRE-AGREED UPON ENDPOINTS PLANNED TO INITIATE IN Q4 2023 WITH TOPLINE DATA EXPECTED MID-2024</p><p>   * ACELRX PHARMACEUTICALS INC - CLINICAL SITE READINESS IS CURRENTLY UNDERWAY</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Acelrx Receives Ide Approval For Niyad And Advances To A Single Registration Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Acelrx Receives Ide Approval For Niyad And Advances To A Single Registration Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2023-10-03 21:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Oct 3 (Reuters) - <a href=\"https://laohu8.com/S/ACRX\">AcelRx Pharmaceuticals</a> Inc   :</p><p>   * ACELRX RECEIVES IDE APPROVAL FOR NIYAD AND ADVANCES TO A SINGLE REGISTRATION STUDY</p><p>   * ACELRX PHARMACEUTICALS - INVESTIGATIONAL DEVICE EXEMPTION APPROVAL BY FDA ALLOWS ACELRX TO BEGIN PIVOTAL STUDY OF NIYAD</p><p>   * ACELRX PHARMACEUTICALS - SINGLE REGISTRATION STUDY WITH PRE-AGREED UPON ENDPOINTS PLANNED TO INITIATE IN Q4 2023 WITH TOPLINE DATA EXPECTED MID-2024</p><p>   * ACELRX PHARMACEUTICALS INC - CLINICAL SITE READINESS IS CURRENTLY UNDERWAY</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2372892255","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2372892255","pubTimestamp":1696338692,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Oct 3  - AcelRx Pharmaceuticals Inc   :   * ACELRX RECEIVES IDE APPROVAL FOR NIYAD AND ADVANCES TO A SINGLE REGISTRATION STUDY   * ACELRX PHARMACEUTICALS - INVESTIGATIONAL DEVICE EXEMPTION APPROVAL BY FDA ALLOWS ACELRX TO BEGIN PIVOTAL STUDY OF NIYAD   * ACELRX PHARMACEUTICALS - SINGLE REGISTRATION STUDY WITH PRE-AGREED UPON ENDPOINTS PLANNED TO INITIATE IN Q4 2023 WITH TOPLINE DATA EXPECTED MID-2024   * ACELRX PHARMACEUTICALS INC - CLINICAL SITE READINESS IS CURRENTLY UNDERWAYSource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药"},"translate_title":"简介-Acelrx获得Ide对Niyad的批准，并推进到单一注册研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACRX":0.9},"content_text":"Oct 3 (Reuters) - AcelRx Pharmaceuticals Inc   :   * ACELRX RECEIVES IDE APPROVAL FOR NIYAD AND ADVANCES TO A SINGLE REGISTRATION STUDY   * ACELRX PHARMACEUTICALS - INVESTIGATIONAL DEVICE EXEMPTION APPROVAL BY FDA ALLOWS ACELRX TO BEGIN PIVOTAL STUDY OF NIYAD   * ACELRX PHARMACEUTICALS - SINGLE REGISTRATION STUDY WITH PRE-AGREED UPON ENDPOINTS PLANNED TO INITIATE IN Q4 2023 WITH TOPLINE DATA EXPECTED MID-2024   * ACELRX PHARMACEUTICALS INC - CLINICAL SITE READINESS IS CURRENTLY UNDERWAYSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}